<p>Evercore ISI 分析师 Elizabeth Anderson CFA 维持了对 HNGE 股票的看涨态度，昨日给予买入评级。</p>
<h3>申请 50% 折扣 TipRanks Premium</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Elizabeth Anderson CFA 给予买入评级的原因包括对 Hinge Health 竞争定位和增长轨迹的信心。她强调，Hinge 的胜率在 2025 年已攀升至约 80%，而 2026 年销售周期的早期反馈信号显示出进一步的势头，支持她认为明年收入可以增长约 25% 的观点，同时运营杠杆也在扩大。</p>
<p>她还强调，Sword Health 收购 Kaia Health 不太可能威胁到 Hinge，因为价格差异保持稳定，行业价格压力似乎有限，数字肌肉骨骼市场仍为多个规模化参与者提供了充足的市场空间。Anderson 预计即将于 2 月 10 日发布的财报和 2026 年展望将成为积极的催化剂，进一步巩固她的 65 美元目标价和买入立场。</p>
<p>在昨日发布的另一份报告中，TipRanks – PerPlexity 也将该股票升级为买入，目标价为 48.00 美元。</p>

GAIA

美国医疗保健供应商 ETF - iShares

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

HNGE

全球科技股指数 ETF - iShares

<p>Evercore ISI 分析师 Elizabeth Anderson 重申了对 Hinge Health (HNGE) 的买入评级，指出其强劲的胜率约为 80%，预计明年的收入增长将达到 25%。她认为，尤其是 Sword Health 收购 Kaia Health 后，竞争威胁有限，这支持她设定的 65 美元目标价。即将于 2 月 10 日发布的财报预计将进一步增强投资者信心。此外，TipRanks 也将 HNGE 升级为买入，目标价为 48 美元</p>

<p>Evercore ISI analyst Elizabeth Anderson CFA has maintained their bullish stance on HNGE stock, giving a Buy rating yesterday.</p>
<div class="lb-trans"><p>Evercore ISI 分析师 Elizabeth Anderson CFA 维持了对 HNGE 股票的看涨态度，昨日给予买入评级。</p>
</div><h3>Claim 50% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>申请 50% 折扣 TipRanks Premium</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Elizabeth Anderson CFA has given his Buy rating due to a combination of factors including confidence in Hinge Health’s competitive positioning and growth trajectory. She emphasizes that Hinge’s win rates have climbed to roughly 80% in 2025 and early feedback from the 2026 selling cycle signals further momentum, supporting her view that revenue can grow about 25% next year while operating leverage expands.</p>
<div class="lb-trans"><p>Elizabeth Anderson CFA 给予买入评级的原因包括对 Hinge Health 竞争定位和增长轨迹的信心。她强调，Hinge 的胜率在 2025 年已攀升至约 80%，而 2026 年销售周期的早期反馈信号显示出进一步的势头，支持她认为明年收入可以增长约 25% 的观点，同时运营杠杆也在扩大。</p>
</div><p>She also underscores that Sword Health’s purchase of Kaia Health is unlikely to threaten Hinge because pricing differentials have remained stable, industry pricing pressure appears limited, and the digital musculoskeletal market still offers ample white space for multiple scaled players. Anderson anticipates the upcoming February 10 earnings release and 2026 outlook to act as a positive catalyst, reinforcing her $65 price target and Buy stance.</p>
<div class="lb-trans"><p>她还强调，Sword Health 收购 Kaia Health 不太可能威胁到 Hinge，因为价格差异保持稳定，行业价格压力似乎有限，数字肌肉骨骼市场仍为多个规模化参与者提供了充足的市场空间。Anderson 预计即将于 2 月 10 日发布的财报和 2026 年展望将成为积极的催化剂，进一步巩固她的 65 美元目标价和买入立场。</p>
</div><p>In another report released yesterday, TipRanks – PerPlexity also upgraded the stock to a Buy with a $48.00 price target.</p>
<div class="lb-trans"><p>在昨日发布的另一份报告中，TipRanks – PerPlexity 也将该股票升级为买入，目标价为 48.00 美元。</p>
</div>

重申对 Hinge Health 的买入评级：强劲的胜率、持续的增长以及有限的竞争威胁支持 65 美元的目标价